|
1
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Demeester SR: Epidemiology and biology of
esophageal cancer. Gastrointest Cancer Res. 32 (Suppl):S2–S5.
2009.
|
|
4
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang F, Yang Z, Cao M, Xu Y, Li J, Chen
X, Gao Z, Xin J, Zhou S, Zhou Z, et al: MiR-203 suppresses tumor
growth and invasion and down-regulates MiR-21 expression through
repressing Ran in esophageal cancer. Cancer Lett. 342:121–129.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iyer RB, Silverman PM, Tamm EP, Dunnington
JS and DuBrow RA: Diagnosis, staging, and follow-up of esophageal
cancer. AJR Am J Roentgenol. 181:785–793. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Subasinghe D and Samarasekera DN: Delay in
the diagnosis of esophageal carcinoma: Experience of a single unit
from a developing country. Indian J Cancer. 47:151–155. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lv XB, Lian GY, Wang HR, Song E, Yao H and
Wang MH: Long noncoding RNA HOTAIR is a prognostic marker for
esophageal squamous cell carcinoma progression and survival. PLoS
One. 8:e635162013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thompson SK, Ruszkiewicz AR, Jamieson GG,
Esterman A, Watson DI, Wijnhoven BP, Lamb PJ and Devitt PG:
Improving the accuracy of TNM staging in esophageal cancer: A
pathological review of resected specimens. Ann Surg Oncol.
15:3447–3458. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li CC, Chen CY and Chien CR: Comparative
effectiveness of image-guided radiotherapy for non-operated
localized esophageal squamous cell carcinoma patients receiving
concurrent chemoradiotherapy: A population-based propensity score
matched analysis. Oncotarget. 7:71548–71555. 2016.PubMed/NCBI
|
|
11
|
Kondo S, Tajika M, Tanaka T, Kodaira T,
Mizuno N, Hara K, Hijioka S, Imaoka H, Goto H, Yamao K and Niwa Y:
Prognostic factors for salvage endoscopic resection for esophageal
squamous cell carcinoma after chemoradiotherapy or radiotherapy
alone. Endosc Int Open. 4:E841–E848. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roeder F, Nicolay NH, Nguyen T,
Saleh-Ebrahimi L, Askoxylakis V, Bostel T, Zwicker F, Debus J,
Timke C and Huber PE: Intensity modulated radiotherapy (IMRT) with
concurrent chemotherapy as definitive treatment of locally advanced
esophageal cancer. Radiat Oncol. 9:1912014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li S, Li Z, Guo F, Qin X, Liu B, Lei Z,
Song Z, Sun L, Zhang HT, You J and Zhou Q: miR-223 regulates
migration and invasion by targeting Artemin in human esophageal
carcinoma. J Biomed Sci. 18:242011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hagman Z, Larne O, Edsjö A, Bjartell A,
Ehrnström RA, Ulmert D, Lilja H and Ceder Y: miR-34c is
downregulated in prostate cancer and exerts tumor suppressive
functions. Int J Cancer. 127:2768–2776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin RJ, Xiao DW, Liao LD, Chen T, Xie ZF,
Huang WZ, Wang WS, Jiang TF, Wu BL, Li EM and Xu LY: MiR-142-3p as
a potential prognostic biomarker for esophageal squamous cell
carcinoma. J Surg Oncol. 105:175–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yokobori T, Suzuki S, Tanaka N, Inose T,
Sohda M, Sano A, Sakai M, Nakajima M, Miyazaki T, Kato H and Kuwano
H: MiR-150 is associated with poor prognosis in esophageal squamous
cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci.
104:48–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hong L, Han Y, Zhang H, Zhao Q and Qiao Y:
miR-210: A therapeutic target in cancer. Expert Opin Ther Targets.
17:21–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li B, Xu WW, Han L, Chan KT, Tsao SW, Lee
NPY, Law S, Xu LY, Li EM, Chan KW, et al: MicroRNA-377 suppresses
initiation and progression of esophageal cancer by inhibiting CD133
and VEGF. Oncogene. 36:3986–4000. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng R, Liu Y, Zhang X, Zhao P and Deng
Q: miRNA-200c enhances radiosensitivity of esophageal cancer by
cell cycle arrest and targeting P21. Biomed Pharmacother.
90:517–523. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shao C, Yu Y, Yu L, Pei Y, Feng Q, Chu F,
Fang Z and Zhou Y: Amplification and up-regulation of microRNA-30b
in oral squamous cell cancers. Arch Oral Biol. 57:1012–1017. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang BY, Zhang XC, Su J, Meng W, Yang XN,
Yang JJ, Zhou Q, Chen ZY, Chen ZH, Xie Z, et al: BCL11A
overexpression predicts survival and relapse in non-small cell lung
cancer and is modulated by microRNA-30a and gene amplification. Mol
Cancer. 12:612013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qi B, Wang Y, Chen ZJ, Li XN, Qi Y, Yang
Y, Cui GH, Guo HZ, Li WH and Zhao S: Down-regulation of
miR-30a-3p/5p promotes esophageal squamous cell carcinoma cell
proliferation by activating the Wnt signaling pathway. World J
Gastroenterol. 23:7965–7977. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu X, Ji Q, Zhang C, Liu X, Liu Y, Liu N,
Sui H, Zhou L, Wang S and Li Q: miR-30a acts as a tumor suppressor
by double-targeting COX-2 and BCL9 in H. pylori gastric cancer
models. Sci Rep. 7:71132017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thomas W: Staging of esophageal cancer:
TNM and beyond. Esophagus. 7:189–195. 2010. View Article : Google Scholar
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wen XP, Ma HL, Zhao LY, Zhang W and Dang
CX: MiR-30a suppresses non-small cell lung cancer progression
through AKT signaling pathway by targeting IGF1R. Cell Mol Biol
(Noisy-le-Grand). 61:78–85. 2015.PubMed/NCBI
|
|
28
|
Wang X, Qiu H, Tang R, Song H, Pan H, Feng
Z and Chen L: miR-30a inhibits epithelial-mesenchymal transition
and metastasis in triple-negative breast cancer by targeting ROR1.
Oncol Rep. 39:2635–2643. 2018.PubMed/NCBI
|
|
29
|
Chiang AC and Massague J: Molecular basis
of metastasis. N Engl J Med. 359:2814–2823. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nguyen DX, Bos PD and Massague J:
Metastasis: From dissemination to organ-specific colonization. Nat
Rev Cancer. 9:274–284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions
the importance of changing cell state in development and disease. J
Clin Invest. 19:1438–1449. 2009. View Article : Google Scholar
|
|
32
|
Yang J and Weinberg RA: Epithelial
mesenchymal transition: At the crossroads of development and tumor
metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S,
Guo X, Wang B, Gang Y, Zhang Y, et al: MiR-218 inhibits invasion
and metastasis of gastric cancer by targeting the robo1 receptor.
PLoS Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu ZL, Wang H, Liu J and Wang ZX:
MicroRNA-21 (miR-21) expression promotes growth, metastasis, and
chemo- or radioresistance in non-small cell lung cancer cells by
targeting PTEN. Mol Cell Biochem. 372:35–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Z, Liu S, Shi R and Zhao G: miR-27
promotes human gastric cancer cell metastasis by inducing
epithelial-to-mesenchymal transition. Cancer Genet. 204:486–491.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sachdeva M and Mo YY: miR-145-mediated
suppression of cell growth, invasion and metastasis. Am J Transl
Res. 2:170–180. 2010.PubMed/NCBI
|
|
38
|
Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo
YY: MicroRNA-21 targets tumor suppressor genes in invasion and
metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Burk U, Schubert J, Wellner U, Schmalhofer
O, Vincan E, Spaderna S and Brabletz T: A reciprocal repression
between ZEBl and membem of the miR-200 family promotes EMT and
invasion in cancer cells. EMBO Rep. 9:582–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Miranda KC, Huynh T, Tay Y, Ang YS, Tam
WL, Thomson AM, Lim B and Rigoutsos I: A pattern-based method for
the identification of MicroRNA binding sites and their
corresponding heteroduplexes. Cell. 126:1203–1217. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu H, Zhao J and Lv J: Inhibitory effects
of miR-101 overexpression on cervical cancer Siha cells. Eur J
Gynaecol Oncol. 38:236–240. 2017.PubMed/NCBI
|
|
43
|
Wang W, Lin H, Zhou L, Zhu Q, Gao S, Xie
H, Liu Z, Xu Z, Wei J, Huang X and Zheng S: MicroRNA-30a-3p
inhibits tumor proliferation, invasiveness and metastasis and is
downregulated in hepatocellular carcinoma. Eur J Surg Oncol.
40:1586–1594. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vandewalle C, Comijn J, De Craene B,
Vermassen P, Bruyneel E, Andersen H, Tulchinsky E, Van Roy F and
Berx G: SIP1/ZEB2 induces EMT by repressing genes of different
epithelial cell-cell junctions. Nucleic Acids Res. 33:6566–6578.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Eades G, Yuan Y, Yang M, Zhang Y, Chumsri
S and Zhou Q: MiR-200a regulates SIRT1 and EMT-like transformation
in mammary epithelial cells. J Biol Chem. 286:25992–6002. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xiang X, Zhuang X, Jiang H, Zhang S, Jiang
H, Mu J, Zhang L, Miller D, Grizzle W and Zhang HG: miR-155
promotes macroscopic tumor formation yet inhibits tumor
dissemination from mammary fat pads to the lung by preventing EMT.
Oncogene. 30:3440–3453. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ke Y, Zhao W, Xiong J and Cao R: miR-149
inhibits non-small-cell lung cancer cells EMT by targeting FOXM1.
Biochem Res Int. 2013:5067312013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yin Z, Zhou B, He Q, Li M, Guan P, Li X,
Cui Z, Xue X, Su M, Ma R, et al: Association between polymorphisms
in DNA repair genes and survival of non-smoking female patients
with lung adenocarcinoma. BMC Cancer. 9:4392009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Connell PP, Kron SJ and Weichselbaum RR:
Relevance and irrelevance of DNA damage response to radiotherapy.
DNA Repair (Amst). 3:1245–1251. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Woodward WA, Chen MS, Behbod F, Alfaro MP,
Buchholz TA and Rosen JM: WNT/beta-catenin mediates radiation
resistance of mouse mammary progenitor cells. Proc Natl Acad Sci
USA. 104:618–623. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Anastasov N, Höfig I, Vasconcellos IG,
Rappl K, Braselmann H, Ludyga N, Auer G, Aubele M and Atkinson MJ:
Radiation resistance due to high expression of miR-21 and G2/M
checkpoint arrest in breast cancer cells. Radiat Oncol. 7:2062012.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Naidu MD, Mason JM, Pica RV, Fung H and
Peña LA: Radiation resistance in glioma cells determined by DNA
damage repair activity of Ape1/Ref-1. J Radiat Res. 51:393–404.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Cho S, Cinghu S, Yu JR and Park WY:
Helicase-like transcription factor confers radiation resistance in
cervical cancer through enhancing the DNA damage repair capacity. J
Cancer Res Clin Oncol. 137:629–637. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hazawa M, Hosokawa Y, Monzen S, Yoshino H
and Kashiwakura I: Regulation of DNA damage response and cell cycle
in radiation-resistant HL60 myeloid leukemia cells. Oncol Rep.
28:55–61. 2012.PubMed/NCBI
|
|
56
|
Liamina D, Sibirnyj W, Khokhlova A, Saenko
V, Rastorgueva E, Fomin A and Saenko Y: Radiation-induced changes
of microRNA expression profiles in radiosensitive and
radioresistant leukemia cell lines with different levels of
chromosome abnormalities. Cancers. 9(pii): E1362017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Liu J, Li M, Wang Y and Luo J: Curcumin
sensitizes prostate cancer cells to radiation partly via epigenetic
activation of miR-143 and miR-143 mediated autophagy inhibition. J
Drug Target. 25:645–652. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hartog H, Wesseling J, Boezen HM and van
der Graaf WT: The insulin-like growth factor 1 receptor in cancer:
Old focus, new future. Eur J Cancer. 43:1895–1904. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bähr C and Groner B: The insulin like
growth factor-1 receptor (IGF-1R) as a drug target: Novel
approaches to cancer therapy. Growth Horm IGF Res. 14:287–295.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lovly CM, McDonald NT, Chen H,
Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang
L, et al: Rationale for co-targeting IGF-1R and ALK in ALK fusion
positive lung cancer. Nat Med. 20:1027–1034. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Buck E and Mulvihill M: Small molecule
inhibitors of the IGF-1R/IR axis for the treatment of cancer.
Expert Opin Investig Drugs. 20:605–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shiratsuchi I, Akagi Y, Kawahara A,
Kinugasa T, Romeo K, Yoshida T, Ryu Y, Gotanda Y, Kage M and
Shirouzu K: Expression of IGF-1 and IGF-1R and their relation to
clinicopathological factors in colorectal cancer. Anticancer Res.
31:2541–2545. 2011.PubMed/NCBI
|
|
63
|
Nussbaum T, Samarin J, Ehemann V,
Bissinger M, Ryschich E, Khamidjanov A, Yu X, Gretz N, Schirmacher
P and Breuhahn K: Autocrine insulin-like growth factor-II
stimulation of tumor cell migration is a progression step in human
hepatocarcinogenesis. Hepatology. 48:146–156. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kim WY, Jin Q, Oh SH, Kim ES, Yang YJ, Lee
DH, Feng L, Behrens C, Prudkin L, Miller YE, et al: Elevated
epithelial insulin-like growth factor expression is a risk factor
for lung cancer development. Cancer Res. 69:7439–7448. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Eckstein N, Servan K, Hildebrandt B,
Pölitz A, von Jonquières G, Wolf-Kümmeth S, Napierski I, Hamacher
A, Kassack MU, Budczies J, et al: Hyperactivation of the
insulin-like growth factor receptor I signaling pathway is an
essential event for cisplatin resistance of ovarian cancer cells.
Cancer Res. 69:2996–3003. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang B, Li Y, Hou D, Shi Q, Yang S and Li
Q: MicroRNA-375 inhibits growth and enhances radiosensitivity in
oral squamous cell carcinoma by targeting insulin like growth
factor 1 receptor. Cell Physiol Biochem. 42:2105–2117. 2017.
View Article : Google Scholar : PubMed/NCBI
|
